Please login to the form below

Not currently logged in
Email:
Password:

Horizon appoints board chair

Dr Ian Gilham assumes position full-time
Horizon Ian Gilham

Horizon Discovery has appointed Dr Ian Gilham as chairman of its board of directors on a permanent basis after he spent several months as its interim chairman.

The UK-based genetic research firm will look to benefit from Dr Gilham's thirty years of industry experience, which includes his role as CEO of in vitro diagnostics company Axis-Shield.

He held this role until from 2008 to 2011, when the company was acquired by Alere.

Dr Gilham's prior experience also includes senior positions at leading pharma companies, such as GlaxoSmithKline and Abbott Labs.

Horizon's CEO Dr Darrin Disley said: “As interim chairman [Dr Gilham] has made an invaluable contribution to the growth and success of the Company and we look forward to benefitting from his guidance as Horizon continues to develop as a world-leading translational genomics organisation."

These growth prospects include a partnership with AstraZeneca to research personalised treatments in oncology.

17th January 2014

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
mXm Medical Communications

mXm Medical Communications meets the needs of pharmaceutical marketers and medics who require a highly experienced, bespoke service from their...

Latest intelligence

Precision paediatrics: Treating patients with CAR-T
Dr Stuart Adams specialises in using T-cell therapy to treat paediatric patients at Great Ormond Street Hospital. Here, he explains what it was like to develop and deliver a groundbreaking...
What does it mean to be an agile organisation
We spoke with Philip Atkinson to learn how healthcare and pharmaceutical companies can rapidly respond to changes in the market....
Battling breast cancer with precision medicine (Part 2)
Dr Mark Moasser treated breast cancer survivor Laura Holmes-Haddad (interviewed in part one) with an innovative precision medicine, which at the time was yet to be approved. Here he gives...

Infographics